Human Wharton's Jelly Stem Cells, its Conditioned Medium and Cell-Free Lysate Inhibit the Growth of Human Lymphoma Cells

Stem Cell Reviews and Reports

Volumn 10, Issue 4, 2014, Pages 573-586

  Lin, Hao Daniel ^a   Fong, Chui Yee ^a   Biswas, Arijit ^a   Choolani, Mahesh ^a   Bongso, Ariff ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cancer cell inhibition; Cell lysate; Conditioned medium; Human Wharton jelly stem cells; Human Wharton s jelly stem cell extracts; Lymphoma

Indexed keywords

CULTURE MEDIUM;

APOPTOSIS; BONE MARROW; CELL CULTURE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE; CULTURE MEDIUM; CYTOLOGY; FEMALE; FIBROBLAST; HUMAN; LYMPHOMA; MESENCHYMAL STROMA CELL; OXIDATIVE STRESS; PATHOLOGY; PHARMACOLOGY; SKIN; UMBILICAL CORD; WHARTON JELLY;

APOPTOSIS; BONE MARROW; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; FEMALE; FIBROBLASTS; HUMANS; LYMPHOMA; MESENCHYMAL STROMAL CELLS; OXIDATIVE STRESS; SKIN; UMBILICAL CORD; WHARTON JELLY;

EID: 84927138002     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-014-9514-3     Document Type: Article

References (79)

1. Lo Celso, C., Wu, J. W., & Lin, C. P. (2009). In vivo imaging of hematopoietic stem cells and their microenvironment. Journal of Biophotonics, 2, 619–31.
2. Gillette, J. M., & Lippincott-Schwartz, J. (2009). Hematopoietic progenitor cells regulate their niche microenvironment through a novel mechanism of cell-cell communication. Communications Integrative Biology, 2, 305–7.
3. Carrancio, S., Blanco, B., Romo, C., Muntion, S., Lopez-Holgado, N., Blanco, J. F., et al. (2011). Bone marrow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: Effect on bone marrow microenvironment. PLoS ONE, 6, e26241.
4. Liu, Y., Chen, X. H., Si, Y. J., Li, Z. J., Gao, L., Gao, L., et al. (2012). Reconstruction of hematopoietic inductive microenvironment after transplantation of VCAM-1-modified human umbilical cord blood stromal cells. PLoS ONE, 7, e31741.
5. O'Flaherty, E., Sparrow, R., & Szer, J. (1995). Bone marrow stromal function from patients after bone marrow transplantation. Bone Marrow Transplantation, 15, 207–12.
6. Guest, I., & Uetrecht, J. (2000). Drugs toxic to the bone marrow that target the stromal cells. Immunopharmacology, 46, 103–12.
7. Tauchmanova, L., Serio, B., Del Puente, A., Risitano, A. M., Esposito, A., De Rosa, G., et al. (2002). Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. Journal of Clinical Endocrinology and Metabolism, 87, 5058–65.
8. Kemp, K., Morse, R., Wexler, S., Cox, C., Mallam, E., Hows, J., et al. (2010). Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy. Annals of Hematology, 89, 701–13.
9. Fritz, V., & Jorgensen, C. (2008). Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Current Stem Cell Research & Therapy, 3, 32–42.
10. Prockop, D. J. (2009). Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Molecular Therapy, 17, 939–46.
11. Wong, R. S. (2011). Mesenchymal stem cells: angels or demons? Journal of Biomedicine and Biotechnology, 2011, 459510.
12. Maestroni, G. J., Hertens, E., & Galli, P. (1999). Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cellular and Molecular Life Sciences, 55, 663–7.
13. Ohlsson, L. B., Varas, L., Kjellman, C., Edvardsen, K., & Lindvall, M. (2003). Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Experimental and Molecular Pathology, 75, 248–55.
14. Khakoo, A. Y., Pati, S., Anderson, S. A., Reid, W., Elshal, M. F., Rovira, I. I., et al. (2006). Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. Journal of Experimental Medicine, 203, 1235–47.
15. Jodele, S., Chantrain, C. F., Blavier, L., Lutzko, C., Crooks, G. M., Shimada, H., et al. (2005). The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Research, 65, 3200–8.
16. Zhang, T., Lee, Y. W., Rui, Y. F., Cheng, T. Y., Jiang, X. H., & Li, G. (2013). Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell Research Therapy, 4, 70.
17. Cardone, A., Tolino, A., Zarcone, R., Borruto Caracciolo, G., & Tartaglia, E. (1997). Prognostic value of desmoplastic reaction and lymphocytic infiltration in the management of breast cancer. Panminerva Medica, 39, 174–7.
18. Bissell, M. J., & Radisky, D. (2001). Putting tumours in context. Nature Reviews Cancer, 1, 46–54.
19. Blankenstein, T. (2005). The role of tumor stroma in the interaction between tumor and immune system. Current Opinion in Immunology, 17, 180–6.
20. Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., et al. (2008). Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Research, 68, 4331–9.
21. Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., et al. (2009). Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE, 4, e4992.
22. Fong, C. Y., Richards, M., Manasi, N., Biswas, A., & Bongso, A. (2007). Comparative growth behaviour and characterization of stem cells from human Wharton's jelly. Reproductive Biomedicine Online, 15, 708–18.
23. Wang, X. Y., Lan, Y., He, W. Y., Zhang, L., Yao, H. Y., Hou, C. M., et al. (2008). Identification of mesenchymal stem cells in aorta-gonad-mesonephros and yolk sac of human embryos. Blood, 111, 2436–43.
24. Fong, C. Y., Subramanian, A., Biswas, A., Gauthaman, K., Srikanth, P., Hande, M. P., et al. (2010). Derivation efficiency, cell proliferation, freeze-thaw survival, stem-cell properties and differentiation of human Wharton's jelly stem cells. Reproductive Biomedicine Online, 21, 391–401.
25. Gauthaman, K., Fong, C. Y., Suganya, C. A., Subramanian, A., Biswas, A., Choolani, M., et al. (2012). Extra-embryonic human Wharton's jelly stem cells do not induce tumorigenesis, unlike human embryonic stem cells. Reproductive Biomedicine Online, 24, 235–46.
26. Wang, Y., Han, Z. B., Ma, J., Zuo, C., Geng, J., Gong, W., et al. (2012). A toxicity study of multiple-administration human umbilical cord mesenchymal stem cells in cynomolgus monkeys. Stem Cells and Development, 21, 1401–8.
27. Chen, H., Zhang, N., Li, T., Guo, J., Wang, Z., Yang, M., et al. (2012). Human umbilical cord Wharton's jelly stem cells: immune property genes assay and effect of transplantation on the immune cells of heart failure patients. Cellular Immunology, 276, 83–90.
28. Wu, K. H., Sheu, J. N., Wu, H. P., Tsai, C., Sieber, M., Peng, C. T., et al. (2013). Cotransplantation of umbilical cord-derived mesenchymal stem cells promote hematopoietic engraftment in cord blood transplantation: a pilot study. Transplantation, 95, 773–777.
29. Rachakatla, R. S., Marini, F., Weiss, M. L., Tamura, M., & Troyer, D. (2007). Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Therapy, 14, 828–35.
30. Ayuzawa, R., Doi, C., Rachakatla, R. S., Pyle, M. M., Maurya, D. K., Troyer, D., et al. (2009). Naive human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Letters, 280, 31–7.
31. Ganta, C., Chiyo, D., Ayuzawa, R., Rachakatla, R., Pyle, M., Andrews, G., et al. (2009). Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. Cancer Research, 69, 1815–20.
32. Maurya, D. K., Doi, C., Kawabata, A., Pyle, M. M., King, C., Wu, Z., et al. (2010). Therapy with un-engineered naive rat umbilical cord matrix stem cells markedly inhibits growth of murine lung adenocarcinoma. BMC Cancer, 10, 590.
33. Sun, B., Yu, K. R., Bhandari, D. R., Jung, J. W., Kang, S. K., & Kang, K. S. (2010). Human umbilical cord blood mesenchymal stem cell-derived extracellular matrix prohibits metastatic cancer cell MDA-MB-231 proliferation. Cancer Letters, 296, 178–85.
34. Ma, Y., Hao, X., Zhang, S., & Zhang, J. (2011). The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells. Breast Cancer Research and Treatment, 133(2), 473–85.
35. Chao, K. C., Yang, H. T., & Chen, M. W. (2012). Human umbilical cord mesenchymal stem cells suppress breast cancer tumourigenesis through direct cell-cell contact and internalization. Journal of Cellular and Molecular Medicine, 16, 1803–15.
36. Gauthaman, K., Fong, C. Y., Cheyyatraivendran, S., Biswas, A., Choolani, M., & Bongso, A. (2012). Human umbilical cord Wharton's jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro. Journal of Cellular Biochemistry, 113, 2027–39.
37. Gauthaman, K., Fong, C. Y., Arularasu, S., Subramanian, A., Biswas, A., Choolani, M., et al. (2013). Human Wharton's jelly stem cell conditioned medium and cell-free lysate inhibit human osteosarcoma and mammary carcinoma cell growth in vitro and in xenograft mice. Journal of Cellular Biochemistry, 114, 366–77.
38. Liu, J., Han, G., Liu, H., & Qin, C. (2013). Suppression of cholangiocarcinoma cell growth by human umbilical cord mesenchymal stem cells: a possible role of Wnt and Akt signaling. PLoS ONE, 8, e62844.
39. Wu, S., Ju, G. Q., Du, T., Zhu, Y. J., & Liu, G. H. (2013). Microvesicles derived from human umbilical cord Wharton's jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo. PLoS ONE, 8, e61366.
40. Subramanian, A., Shu-Uin, G., Kae-Siang, N., Gauthaman, K., Biswas, A., Choolani, M., et al. (2012). Human umbilical cord Wharton's jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells. Journal of Cellular Biochemistry, 113, 1886–95.
41. Nekanti, U., Rao, V. B., Bahirvani, A. G., Jan, M., Totey, S., & Ta, M. (2010). Long-term expansion and pluripotent marker array analysis of Wharton's jelly-derived mesenchymal stem cells. Stem Cells and Development, 19, 117–30.
42. Fong, C. Y., Chak, L. L., Biswas, A., Tan, J. H., Gauthaman, K., Chan, W. K., et al. (2011). Human Wharton's jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Reviews, 7, 1–16.
43. Kawabata, A., Ohta, N., Seiler, G., Pyle, M. M., Ishiguro, S., Zhang, Y. Q., et al. (2013). Naive rat umbilical cord matrix stem cells significantly attenuate mammary tumor growth through modulation of endogenous immune responses. Cytotherapy, 15, 586–97.
44. Secchiero, P., Zorzet, S., Tripodo, C., Corallini, F., Melloni, E., Caruso, L., et al. (2010). Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS ONE, 5, e11140.
45. Fonseka, M., Ramasamy, R., Yip, W. K., Tan, B. C., & Seow, H. F. (2012). Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSC) inhibit the proliferation of K562 (Human erythromyeloblastoid leukemic cell line). Cell Biology Intnl, 36, 793–801.
46. Fong, C. Y., Gauthaman, K., Cheyyatraivendran, S., Lin, H. D., Biswas, A., & Bongso, A. (2012). Human umbilical cord Wharton's jelly stem cells and its conditioned medium support hematopoietic stem cell expansion ex vivo. Journal of Cellular Biochemistry, 113, 658–68.
47. Yang, H. T., & Chao, K. C. (2013). Foetal defence against cancer: a hypothesis. Journal of Cellular and Molecular Medicine, 17, 1096–8.
48. Potter, J. F., & Schoeneman, M. (1970). Metastasis of maternal cancer to the placenta and fetus. Cancer, 25, 380–8.
49. Dildy, G. A., 3rd, Moise, K. J., Jr., Carpenter, R. J., Jr., & Klima, T. (1989). Maternal malignancy metastatic to the products of conception: a review. Obstetrical and Gynecological Survey, 44, 535–40.
50. Alexander, A., Samlowski, W. E., Grossman, D., Bruggers, C. S., Harris, R. M., Zone, J. J., et al. (2003). Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. Journal of Clinical Oncology, 21, 2179–86.
51. Jackisch, C., Louwen, F., Schwenkhagen, A., Karbowski, B., Schmid, K. W., Schneider, H. P., et al. (2003). Lung cancer during pregnancy involving the products of conception and a review of the literature. Archives of Gynecology and Obstetrics, 268, 69–77.
52. Liu, J., & Guo, L. (2006). Intraplacental choriocarcinoma in a term placenta with both maternal and infantile metastases: a case report and review of the literature. Gynecologic Oncology, 103, 1147–51.
53. Henry, F., Bretaudeau, L., Barbieux, K., Meflah, K., & Gregoire, M. (1998). Induction of antigen presentation by macrophages after phagocytosis of tumorapoptotic cells. Research in Immunology, 149, 673–9.
54. Chan J, Harrison JS, Ponzio NM, Rameshwar P. Mesenchymal stem cells (MSC) exhibit antigen presenting (APC) and phagocytic properties: Implications to bone marrow failure during inflammation. Blood 104: Abstract 4249.
55. Barker, R. N., Erwig, L. P., Hill, K. S., Devine, A., Pearce, W. P., & Rees, A. J. (2002). Antigen presentation by macrophages is enhanced by the uptake of necrotic, but not apoptotic, cells. Clinical and Experimental Immunology, 127, 220–5.
56. Weiss, M. L., Anderson, C., Medicetty, S., Seshareddy, K. B., Weiss, R. J., & Vanderwerff, I. (2008). Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells, 26, 2865–2874.
57. Bewick, M., Coutie, W., & Tudhope, G. R. (1987). Superoxide dismutase, glutathione peroxidase and catalase in the red cells of patients with malignant lymphoma. British Journal of Haematology, 65, 347–50.
58. Oberley, L. W. (2001). Anticancer therapy by overexpression of superoxide dismutase. Antioxidants and Redox Signaling, 3, 461–72.
59. Bakan, N., Taysi, S., Yilmaz, O., Bakan, E., Kuskay, S., Uzun, N., et al. (2003). Glutathione peroxidase, glutathione reductase, Cu-Zn superoxide dismutase activities, glutathione, nitric oxide, and malondialdehyde concentrations in serum of patients with chronic lymphocytic leukemia. Clinica Chimica Acta, 338, 143–9.
60. Davicino, R., Manuele, M. G., Turner, S., Ferraro, G., & Anesini, C. (2010). Antiproliferative activity of Larrea divaricata Cav. on lymphoma cell line: participation of hydrogen peroxide in its action. Cancer Investigation, 28, 13–22.
61. Zhong, W., Oberley, L. W., Oberley, T. D., & St Clair, D. K. (1997). Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene, 14, 481–90.
62. Zhong, W., Oberley, L. W., Oberley, T. D., Yan, T., Domann, F. E., & St Clair, D. K. (1996). Inhibition of cell growth and sensitization to oxidative damage by overexpression of manganese superoxide dismutase in rat glioma cells. Cell Growth and Differentiation, 7, 1175–86.
63. Tome, M. E., Jaramillo, M. C., & Briehl, M. M. (2011). Hydrogen peroxide signaling is required for glucocorticoid-induced apoptosis in lymphoma cells. Free Radical Biology and Medicine, 51, 2048–59.
64. Tome, M. E., Lee, K., Jaramillo, M. C., & Briehl, M. M. (2012). Mitochondria are the primary source of the H(2)O(2) signal for glucocorticoid-induced apoptosis of lymphoma cells. Experiment Therapeutica Medicine, 4, 237–242.
65. Vogelzang NJ. 1991. Nephrotoxicity from chemotherapy: prevention and management. Oncology (Williston Park) 5:97-102, 105; disc 105, 109-11.
66. Takimoto, C. H., Lu, Z. H., Zhang, R., Liang, M. D., Larson, L. V., Cantilena, L. R., Jr., et al. (1996). Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clinical Cancer Research, 2, 477–81.
67. Takemura, G., & Fujiwara, H. (2007). Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Progress in Cardiovascular Diseases, 49, 330–52.
68. Di, G. H., Jiang, S., Li, F. Q., Sun, J. Z., Wu, C. T., Hu, X., et al. (2012). Human umbilical cord mesenchymal stromal cells mitigate chemotherapy-associated tissue injury in a pre-clinical mouse model. Cytotherapy, 14, 412–22.
69. Chamberlin, W., Barone, J., Kedo, A., & Fried, W. (1974). Lack of recovery of murine hematopoietic stromal cells after irradiation-induced damage. Blood, 44, 385–92.
70. Wolf, N. S. (1982). Dissecting the hematopoietic microenvironment. V: limitations of repair following damage to the hematopoietic support stroma. Experimental Hematology, 10, 108–18.
71. Gibson, L. F., Fortney, J., Landreth, K. S., Piktel, D., Ericson, S. G., & Lynch, J. P. (1997). Disruption of bone marrow stromal cell function by etoposide. Biology of Blood and Marrow Transplantation, 3, 122–32.
72. Galotto, M., Berisso, G., Delfino, L., Podesta, M., Ottaggio, L., Dallorso, S., et al. (1999). Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Experimental Hematology, 27, 1460–6.
73. Friedman, R., Betancur, M., Boissel, L., Tuncer, H., Cetrulo, C., & Klingemann, H. (2007). Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation. Biology of Blood and Marrow Transplantation, 13, 1477–86.
74. Le Blanc, K., Samuelsson, H., Gustafsson, B., Remberger, M., Sundberg, B., Arvidson, J., et al. (2007). Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia, 21, 1733–8.
75. Lee, S. H., Lee, M. W., Yoo, K. H., Kim, D. S., Son, M. H., Sung, K. W., et al. (2013). Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation. Bone Marrow Transplantation, 48, 1040–5.
76. Fan, C. G., Zhang, Q., & Zhou, J. (2011). Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord. Stem Cell Reviews and Reports, 7, 195–207.
77. Chao, Y. H., Tsai, C., Peng, C. T., Wu, H. P., Chan, C. K., Weng, T., et al. (2011). Cotransplantation of umbilical cord MSCs to enhance engraftment of hematopoietic stem cells in patients with severe aplastic anemia. Bone Marrow Transplantation, 46, 1391–2.
78. Hu, J., Yu, X., Wang, Z., Wang, F., Wang, L., Gao, H., et al. (2013). Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocrine Journal, 60, 347–57.
79. Dalous, J., Larghero, J., & Baud, O. (2012). Transplantation of umbilical cord-derived mesenchymal stem cells as a novel strategy to protect the central nervous system: technical aspects, preclinical studies, and clinical perspectives. Pediatric Research, 71, 482–90.